Blog Network

Upcoming Events

About

The Future of BioPharma blog provides timely coverage of news that directly impacts the business strategies of the biotech, pharmaceutical and medical device industries. In addition to news coverage, the Future of BioPharma blog features live event coverage from IIR's Biopharmaceutical and Healthcare division.

Tuesday, September 1, 2015

Lin Zang, Senior Scientist, Analytical Development, Biogen describes
the mass spectrometry workflow for host cell protein identification that she
will be presenting on at the BioProcess International Conference &
Exposition, and discusses the implications of HCPs on downstream process
development.

The big challenge in downstream process development
concerning host cell proteins is that the amount of HCPs in the purified
product is often so low that it is hard to determine the identity of the HCP. Min
Zhu, Senior Scientist, Purification Process Sciences, MedImmune LLC, describes
how the approach she will be presenting at the conference overcomes this
challenge.

Implementing
Multi-Attribute LC/MS Methods for More Informed Process Development

Matthew Traylor, Analytical Scientist, Process Development,
Shire, discusses how he gets a deep characterization a specific protein out of
a mixture, using LC/MS software packages that automate the process. He shares
how this technology can be used at laboratory, pilot and production scale process
development.

Hear more from Matthew at 9:20 am on Tuesday, October 27,
2015 at BPI.

Carly Cox, Senior Process Engineer, Pfizer, describes what a
CPV informatics system is and how it’s used in product manufacturing. She’ll be
presenting at the BioProcess International Conference on how multiple source
systems can pull data on product manufacturing processing and be collected into
a CPV informatics system, and some of the important areas to consider for
validation and configuration for regulatory reporting and process monitoring.

Hear more from Carly at 9:20 am on Wednesday, October 28,
2015 at BPI.

Hear about how a risk based approach to autologous cell
therapy products used at Vericel. In this podcast, John Duguid, Principal
Scientist, Vericel Corporation, describes how rapid microbiological methods are
used in product release of autologous cell therapy products, and discusses the
areas of contamination risk. Audio Player

If you haven’t
already, register for BPI 2015 taking place this fall in Boston. BPI is
engineered to be exactly what YOU need it to be. Formal and informal networking
experiences connect you to peers, prospects, and customers. Parallel tracks
give you the option to dive deep or take a big picture approach to learn about
industry trends, challenges, and benchmark against the latest research
developments. Big pharma and large, mid-size and emerging biotechs
collaborating with solution providers featuring proven and next generation
technologies make BPI a one-of-a-kind meeting place.As a valued reader of our
blog, you get an exclusive $100 off the current rate when you use code
XB15171BLOG. Register here: http://bit.ly/1JA9EQe